Company intelligence / Profile preview

Regeneron Pharmaceuticals

Tarrytown, New York, United Statesregeneron.com ↗

Ownership: Public · REGN
Employees: ~15100
Development stage: Commercial

Overview

Regeneron has several approved drugs including aflibercept (EYLEA) for eye diseases, rilonacept (ARCALYST) for rare autoinflammatory diseases, dupilumab (Dupixent) for allergic conditions, and cemiplimab (Libtayo) for cancer. The company has demonstrated strong efficacy and reached blockbuster status for EYLEA and Dupixent while rapidly advancing innovative candidates from genetics and antibody platforms. EYLEA HD (high dose) was approved in 2023; rapid COVID-19 therapeutics such as REGEN-COV have also been deployed in response to global needs.

Therapeutic areas: ImmunologyOphthalmologyInfectious DiseasesHematologyCardiovascularOncologyNeurology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyTrap fusion proteinGene therapyBiologicSmall molecule
Industry: Pharma

Drug pipeline

129 assets

dupilumab

Approved

128 more assets in the full pipeline.

Request access →

Partnerships

SanofiBayerTeva Pharmaceutical Industries

Beyond the preview

Go deeper on Regeneron Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regeneron Pharmaceuticals.

Explore the full profile